EFSA concluded it could not assess the safety of E140(ii) chlorophyllins
When EFSA reviewed all chlorophyll-based food additives in 2015, it reached sharply different conclusions for the two sub-types. For E140(i) chlorophylls it noted data limitations but considered exposure low enough to be acceptable. For E140(ii) chlorophyllins it went further, concluding that a safety assessment was not possible at all, because there are no data on how the compound is absorbed, distributed, broken down or excreted in the human body, and because chlorophyllins are not a natural dietary constituent or a known human metabolite. The European Commission issued a follow-up call for data in 2017, but no new EFSA opinion on E140(ii) has been published as of mid-2026.
EFSA concluded that it was not possible to assess the safety of chlorophyllins (E140(ii)) as food additives, citing the complete absence of ADME and toxicity data and the fact that chlorophyllins are neither natural dietary constituents nor human metabolites of chlorophylls.
2015Regulatory reviewEFSA Panel on Food Additives and Flavourings, Scientific Opinion on re-evaluation of chlorophyllins (E140(ii)) as food additives, EFSA Journal 2015;13(5):4085
For E140(i) chlorophylls, EFSA found the toxicological database inadequate for a risk assessment; no numerical ADI was established. Up to 90% of the extract is unidentified, and the extraction source materials (grass, lucerne, nettle) are not conventional human foods.
2015Regulatory reviewEFSA Panel on Food Additives and Flavourings, Scientific Opinion on re-evaluation of chlorophylls (E140(i)) as food additives, EFSA Journal 2015;13(5):4089
Potential contaminants in the extract
Because E140(i) is extracted from crops such as grass and alfalfa, EFSA flagged that pesticide residues, mycotoxins and compounds with biological activity including phytoestrogens, phytotoxins and allergens may carry through into the final additive. The specifications do not currently require testing for most of these, and EFSA called for data on their levels. This does not establish a proven harm from typical food exposures but it is an unresolved gap in the regulatory picture.
EFSA noted that data on pesticides, mycotoxins and other biologically active components including phytoestrogens, phytotoxins and allergens should be included in the E140(i) specification and kept as low as possible.
2015Regulatory reviewEFSA Panel on Food Additives and Flavourings, Scientific Opinion on re-evaluation of chlorophylls (E140(i)) as food additives, EFSA Journal 2015;13(5):4089
Laboratory and clinical evidence on antimutagenic activity
Chlorophyllin (the sodium-magnesium form used in research, related to E140(ii)) has been studied for its ability to bind to dietary carcinogens and reduce their absorption. A randomised trial in Qidong, China, where residents face high aflatoxin exposure from contaminated grain, found that taking chlorophyllin tablets reduced measurable aflatoxin-DNA damage markers in urine by about 55%. This is a specific chemopreventive context, not a general property of E140 as used in food colouring doses.
In a randomised double-blind placebo-controlled trial in 180 adults in Qidong, China, 100mg chlorophyllin three times daily for four months reduced urinary aflatoxin-DNA adducts by approximately 55% compared with placebo.
2001RCTEgner PA et al., Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer, Proceedings of the National Academy of Sciences
Chlorophyllin showed 90-100% inhibition of the mutagenic activity of complex mixtures including fried meat extracts and cigarette smoke condensate in laboratory mutagenicity assays.
LabAntimutagenic Effects of Chlorophyllin, Springer Nature